Cartography Biosciences develops precision cancer immunotherapies. It identifies therapeutic targets by analyzing cancers through antigen expression instead of histology or genetic mutations, enabling therapies that specifically engage tumor cells while aiming to minimize harm to healthy tissue. The company designs and commercializes targeted immunotherapies and seeks druggable targets in cancers that are currently untreatable, striving for treatments that are as safe as they are effective and broadly applicable across tumor cells within a patient. In short, its goal is to deliver precise, safe, and potent cancer treatments by pairing a unique target-identification approach with immunotherapy platforms, and to bring these therapies to healthcare providers and patients through commercialization.
Company Size
51-200
Company Stage
Series B
Total Funding
$124M
Headquarters
Foster City, California
Founded
2020
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?